It looks like nothing was found at this location. Maybe try one of the links below or a search?
Popular Articles:
-
Response to EPO consultation: Don’t impose oral proceedings by videoconference
-
Quality at the EPO – One Modest and one Serious Proposal
-
‘Opposition against Unitary Patent comes from fearful lawyers and critics who only have a theoretical interest’
-
Leading German patent law firms criticize European Patent Office
-
UPC: four reasons on why the PPA is not legally in force
-
The EPO’s Vision (V) – Trust
Recent Articles:
-
Announcement of the national program “MOVER” raises expectations for an increase in patent filings for green technology
-
UPC “saisie-contrefaçon” Part III: the “C-Kore” case
-
Brazil: Animal Health and Patent Litigation
-
China’s Supreme People Court decides FRAND dispute in ACT v Oppo
-
UPC “saisie-contrefaçon” Part II: the “OERLIKON” case
-
UPC “saisie-contrefaçon” Part I: the texts
Random Articles:
-
German Federal Patent Court outlines detailed guidelines for royalty rates
-
First developments at the Unified Patent Court
-
Dipeptidyl-Peptidase-Inhibitoren, Federal Court of Justice Germany, 11 September 2013
-
When ‘Nature’ attacks the ‘Hill of Testimony’…
-
T1713/11, European Patent Office (Appeals Court), 12 December 2012
-
German court reverses decision on pemetrexed dipotassium (Eli Lilly v Actavis)
-
Specification may not normally be used to restrict the scope of protection of claims
-
US Food Drug Administration will follow EMA and relocate in Amsterdam
-
Patent case: Kerr Corp. vs. RPE GmbH, EPO
-
Patent case: NanoString Technologies vs. 10x Genomics and President and Fellows of Harvard College, UPC